Endo divests Paladin business

11 March 2025

USA-based Endo Inc (OTCQX: NDOI) today announced it has entered into a definitive agreement to divest its international pharmaceuticals business, primarily operated through Canada-based specialty pharmaceutical company Paladin Pharma to Knight Therapeutics (TSX: GUD),

The total consideration is of up to $99 million, consisting of an upfront cash payment of $84 million and up to an additional $15 million in potential future payments contingent upon the achievement of certain milestones.

Knight Therapeutics is a specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and commercializing innovative prescription pharmaceuticals, primarily serving Canada and Latin America.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK